145 related articles for article (PubMed ID: 9349378)
1. Acceleration of leukaemia with granulocyte colony-stimulating factor in a patient with aleukaemic leukaemia.
Fata F; Myers P; Addeo J; Nawabi I
Br J Hosp Med; 1997 Jul 9-Aug 19; 58(2-3):111-2. PubMed ID: 9349378
[No Abstract] [Full Text] [Related]
2. [In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia].
Takeyama H; Kajiguchi T; Miyata Y; Saito M
Gan To Kagaku Ryoho; 2000 Jun; 27(6):873-8. PubMed ID: 10897214
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Milligan DW; Wheatley K; Burnett AK
Br J Haematol; 2004 Oct; 127(2):238-9. PubMed ID: 15461640
[No Abstract] [Full Text] [Related]
6. Aberrant phenotype of plasmacytoid monocytes in acute myeloid leukemia.
Boveri E; Castagnola C; Castello A; Magrini U
Am J Hematol; 2008 May; 83(5):428-9. PubMed ID: 17617786
[No Abstract] [Full Text] [Related]
7. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
8. [FLAG regimen in the treatment of refractory and relapsed acute myeloid leukemia].
Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):1-2. PubMed ID: 21429391
[No Abstract] [Full Text] [Related]
9. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
10. Successful combination therapy with infusion of allogenetic bone marrow mesenchymal stem cells and CAG regimen in hypoplastic relapsed acute myelogenous leukemia.
Lu H; Lu SF; Shen WY; Hong M; Zhang JF; Wang LX; Yang H; Li JY
Leuk Res; 2008 Nov; 32(11):1776-9. PubMed ID: 18501425
[No Abstract] [Full Text] [Related]
11. Lineage switch and multilineage involvement in two cases of pH chromosome-positive acute leukemia: evidence for a stem cell disease.
Cuneo A; Balboni M; Piva N; Carli MG; Tomasi P; Previati R; Negrini M; Scapoli G; Spanedda R; Castoldi G
Haematologica; 1994; 79(1):76-82. PubMed ID: 15378954
[TBL] [Abstract][Full Text] [Related]
12. Neutrophilic dermatoses with acute myeloid leukemia associated with an increase of serum colony-stimulating factor.
Uhara H; Saida T; Nakazawa H; Ito T
J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S10-2. PubMed ID: 18625369
[TBL] [Abstract][Full Text] [Related]
13. Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
Tatetsu H; Matsuno F; Takatsu N; Miyake H; Hoshino K; Nosaka K; Horikawa K; Hata H; Mitsuya H; Asou N
Leuk Res; 2009 Jan; 33(1):197-200. PubMed ID: 18472159
[No Abstract] [Full Text] [Related]
14. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
[TBL] [Abstract][Full Text] [Related]
15. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
[TBL] [Abstract][Full Text] [Related]
16. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
17. [Acute myeloblastic leukemia showing pronounced skin infiltration during administration of low-dose cytarabine and etoposide with granulocyte colony-stimulating factor].
Kawachi Y; Kuwajima Y; Nishihara T; Uchida T; Setsu K; Mori M; Ikeda K; Ikeda T; Sasaki K; Takahara J
Rinsho Ketsueki; 1997 Sep; 38(9):763-9. PubMed ID: 9364868
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
19. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
[TBL] [Abstract][Full Text] [Related]
20. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
